Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 36.84% and 3.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Amicus approval gets delayed again because the FDA cannot inspect a Chinese facility. China's zero COVID policy is to blame.

U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease

08:01pm, Friday, 28'th Oct 2022 GlobeNewswire Inc.
FDA Issues Deferred Action Letter on AT-GAA Regulatory Filing Due to the Inability to Conduct Required Manufacturing Site Inspection Prior to the PDUFA Action Date
PHILADELPHIA, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, November 7, 2022 at 8:
WASHINGTON (AP) — The Onion has some serious things to say in defense of parody.
Upgrades For 3M Co (NYSE:MMM), UBS upgraded the previous rating of Sell to Neutral. For the second quarter, 3M had an EPS of $2.48, compared to year-ago quarter EPS of $2.59. The current stock perform
PHILADELPHIA, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthc
A strategy selecting 10 of the 50 stocks, equally weighted, would have increased total return to 178.0%, an active return of 61.6% vs. SPY.
U.S. stocks closed mixed on Friday following the release of jobs data for July. Here is the list of some big stocks moving higher in the previous session. Carvana Co. (NYSE: CVNA) jumped 40.1% to clo
Gainers Cooper-Standard Holdings Inc. (NYSE: CPS) jumped 69.6% to close at $8.53 on Friday following better-than-expected Q2 results. Intelligent Living Application Group Inc. (NASDAQ: ILAG) surged 6

Amicus (FOLD) Q2 Earnings Beat, Galafold Sales Miss Estimates

03:55pm, Friday, 05'th Aug 2022 Zacks Investment Research
Amicus Therapeutics (FOLD) posts a narrower-than-expected loss for the second quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.
Amicus Therapeutics (FOLD) posts a narrower-than-expected loss for the second quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.
Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Andrew Faughnan - Senior Director, IR Bradley Campbell - CEO, President & Direc

Amicus Therapeutics (FOLD) Reports Q2 Loss, Lags Revenue Estimates

12:35pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 8.70% and 5.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Amicus Therapeutics Announces Second Quarter 2022 Financial Results

11:00am, Thursday, 04'th Aug 2022 GlobeNewswire Inc.
1H22 Galafold® Revenue of $159.4M, reflecting 11% Sales Growth with Operational Growth of 18%, Partly Offset by Currency Headwinds of 7%
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE